Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934814 · ClinicalTrials.gov registry record · Phase 1
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 study, sponsored by I-Mab Biopharma US Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT03934814 is a Phase 1 study that has completed, run by I-Mab Biopharma US Limited. The registered enrollment target is 98 participants.
The verdict
NCT03934814, a Phase 1 study, has completed, sponsored by I-Mab Biopharma US Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
Interventions
- DRUG Pembrolizumab
- DRUG Rituximab
- DRUG TJ011133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03934814
The ClinicalTrials.gov registry entry for NCT03934814 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is I-Mab Biopharma US Limited, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03934814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03934814 about?
NCT03934814 is a clinical study titled "Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma". The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
What is the current status of trial NCT03934814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2019-04-16. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT03934814?
The interventions under investigation include: Pembrolizumab (DRUG), Rituximab (DRUG), TJ011133 (DRUG).
Who is sponsoring clinical trial NCT03934814?
This trial is sponsored by I-Mab Biopharma US Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.